JP2022538228A5 - - Google Patents
Info
- Publication number
- JP2022538228A5 JP2022538228A5 JP2021576576A JP2021576576A JP2022538228A5 JP 2022538228 A5 JP2022538228 A5 JP 2022538228A5 JP 2021576576 A JP2021576576 A JP 2021576576A JP 2021576576 A JP2021576576 A JP 2021576576A JP 2022538228 A5 JP2022538228 A5 JP 2022538228A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- linear
- compound
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181952.3 | 2019-06-24 | ||
| EP19181952 | 2019-06-24 | ||
| PCT/EP2020/067451 WO2020260252A1 (en) | 2019-06-24 | 2020-06-23 | New macrocyclic compounds and derivatives as egfr inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538228A JP2022538228A (ja) | 2022-09-01 |
| JP2022538228A5 true JP2022538228A5 (https=) | 2023-06-26 |
| JP7590996B2 JP7590996B2 (ja) | 2024-11-27 |
Family
ID=67003267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576576A Active JP7590996B2 (ja) | 2019-06-24 | 2020-06-23 | Ｅｇｆｒ阻害剤としての新たな大環状化合物および誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12522615B2 (https=) |
| EP (1) | EP3986564A1 (https=) |
| JP (1) | JP7590996B2 (https=) |
| CN (1) | CN114007698B (https=) |
| WO (1) | WO2020260252A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4079735B1 (en) | 2019-12-16 | 2025-08-06 | Beijing Tide Pharmaceutical Co., Ltd. | Macrocyclic compounds for inhibiting and inducing degradation of egfr kinase in the treatment of cancer |
| CN113880804A (zh) * | 2020-07-01 | 2022-01-04 | 微境生物医药科技(上海)有限公司 | 新型苯并咪唑化合物 |
| CN114163454B (zh) * | 2020-09-11 | 2026-01-02 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物抑制剂、其制备方法和应用 |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| CN114057771B (zh) * | 2020-12-03 | 2023-10-03 | 北京鞍石生物科技有限责任公司 | 大环化合物及其制备方法和应用 |
| CN114656482B (zh) * | 2020-12-23 | 2025-10-17 | 南京圣和药业股份有限公司 | 作为egfr抑制剂的大环杂环类化合物及其应用 |
| CN116761603A (zh) * | 2021-02-06 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途 |
| CN114907379B (zh) * | 2021-02-06 | 2026-04-17 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的大环化合物 |
| AU2022230397A1 (en) * | 2021-03-02 | 2023-09-21 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
| IL306067A (en) * | 2021-03-26 | 2023-11-01 | Theseus Pharmaceuticals Inc | Macrocyclic egfr inhibitors for the treatment of cancer |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN115368378B (zh) * | 2021-05-21 | 2024-11-19 | 深圳市塔吉瑞生物医药有限公司 | 取代的大环化合物及包含该化合物的组合物及其用途 |
| IL309040A (en) * | 2021-06-30 | 2024-02-01 | Aqilion Ab | Macrocyclic TAK1 inhibitors |
| WO2023001069A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 大环酰胺类化合物及其应用 |
| TW202330550A (zh) * | 2021-11-30 | 2023-08-01 | 大陸商正大天晴藥業集團股份有限公司 | 含有環烷基或鹵代烷基的化合物 |
| US20250282795A1 (en) * | 2022-04-20 | 2025-09-11 | Celyn Therapeutics, Inc. | EGFR Inhibitors in cancer treatment |
| CN117024443A (zh) * | 2022-05-09 | 2023-11-10 | 元启(苏州)生物制药有限公司 | Egfr抑制剂及其用途 |
| CN119522227A (zh) * | 2022-07-21 | 2025-02-25 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| CN119487039A (zh) | 2022-07-21 | 2025-02-18 | 贝达药业股份有限公司 | 大环化合物及其药物组合物和应用 |
| TW202416963A (zh) * | 2022-09-02 | 2024-05-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｇｆｒ抑制劑及其用途 |
| WO2024078263A1 (zh) * | 2022-10-09 | 2024-04-18 | 药雅科技(上海)有限公司 | 大环杂环类化合物作为egfr抑制剂的制备及其应用 |
| CN117229300A (zh) * | 2023-03-12 | 2023-12-15 | 药雅科技(上海)有限公司 | Egfr抑制剂的制备及其应用 |
| WO2024099402A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| WO2024099400A1 (en) * | 2022-11-10 | 2024-05-16 | Beigene (Beijing) Co., Ltd. | Intermediates and process of compounds for the degradation of egfr kinase |
| TW202428267A (zh) * | 2022-11-10 | 2024-07-16 | 英屬開曼群島商百濟神州有限公司 | 用於降解ｅｇｆｒ激酶之化合物 |
| CN118324778A (zh) * | 2023-04-25 | 2024-07-12 | 苏州共康医药科技有限公司 | 第四代egfr抑制剂 |
| EP4720071A1 (en) * | 2023-05-31 | 2026-04-08 | Beone Medicines I GmbH | Compounds for the degradation of egfr kinase |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| JP2005509003A (ja) | 2001-11-09 | 2005-04-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物 |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| AU2003257094A1 (en) | 2002-08-08 | 2004-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| WO2005070420A1 (en) | 2004-01-14 | 2005-08-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| WO2005079791A1 (en) | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| WO2007133983A2 (en) | 2006-05-08 | 2007-11-22 | Pharmacopeia, Inc. | 2-aminobenzimidazoles for treating neurodegenerative diseases |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| CN103159742B (zh) * | 2011-12-16 | 2015-08-12 | 北京韩美药品有限公司 | 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用 |
| US20150152083A1 (en) | 2012-06-06 | 2015-06-04 | Irm Llc, A Delaware Limited Liability Company | Compounds and Compositions for Modulating EGFR Activity |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| US9573958B2 (en) * | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| WO2014081718A1 (en) | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| HRP20171302T1 (hr) | 2013-02-07 | 2017-10-20 | Merck Patent Gmbh | Makrociklički derivati piridazinona |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| CN104513253A (zh) | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| CA2943220C (en) | 2014-03-20 | 2024-01-16 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| JP6568926B2 (ja) | 2014-03-20 | 2019-08-28 | カペラ セラピューティクス，インコーポレーテッド | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
| WO2016176473A1 (en) | 2015-04-28 | 2016-11-03 | Sanford-Burnham Medical Researc Institute | Apelin receptor agonists and methods of use thereof |
| CN108012529A (zh) | 2015-05-15 | 2018-05-08 | 诺华股份有限公司 | 治疗egfr突变的癌症的方法 |
| JP6845165B2 (ja) | 2015-06-30 | 2021-03-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｅｇｆｒ阻害剤およびその使用方法 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| BR112018003812B1 (pt) | 2015-09-18 | 2024-04-30 | Merck Patent Gmbh | Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit |
| CN108602776B (zh) | 2015-09-18 | 2021-12-03 | 默克专利有限公司 | 用作irak抑制剂的杂芳基化合物及其用途 |
| RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| US11083793B2 (en) | 2016-12-13 | 2021-08-10 | Health Research, Inc. | Epidermal growth factor receptor (EGFR) targeted photosensitizers |
-
2020
- 2020-06-23 WO PCT/EP2020/067451 patent/WO2020260252A1/en not_active Ceased
- 2020-06-23 JP JP2021576576A patent/JP7590996B2/ja active Active
- 2020-06-23 US US17/621,420 patent/US12522615B2/en active Active
- 2020-06-23 CN CN202080045795.1A patent/CN114007698B/zh active Active
- 2020-06-23 EP EP20734188.4A patent/EP3986564A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538228A5 (https=) | ||
| JP2024543982A5 (https=) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2013512903A5 (https=) | ||
| JP2022520061A5 (https=) | ||
| JP2024521706A5 (https=) | ||
| JP2016509047A5 (https=) | ||
| JP2021523112A5 (https=) | ||
| JP2022515197A5 (https=) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2017504642A5 (https=) | ||
| JP2018528261A5 (https=) | ||
| RU2012138709A (ru) | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения | |
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| RU2013148922A (ru) | Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства | |
| JP2017503803A5 (https=) | ||
| RU2016102036A (ru) | Производное хинолина | |
| JP2016513137A5 (https=) | ||
| JP2021531311A5 (https=) | ||
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2020500866A5 (https=) | ||
| CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives |